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with sufficiently long duration to cover a mortgage is feasible for many HIV-positive
people successfully treated with ART for more than 6 months.
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Since its introduction in 1996, improvements to
combination antiretroviral therapy (ART) such as new
regimens [1] and one pill per day coformulations [2] have
led to improved prognosis and better adherence to
treatment [3]. Rates of mortality among HIV-positive
people have declined sufficiently dramatically [4,5] to
justify the introduction of limited life insurance for HIV-
positive applicants who are not coinfected with hepatitis
C virus (HCV) [6]. On the basis of estimated standardized
mortality ratios for nine countries, a recent study
concluded that a significant proportion of HIV-positive
individuals experience similar mortality to those with
other conditions requiring lifelong treatment, such as
diabetes [7]. However, access to life insurance remains
limited.
Analyses of data from cohorts of treated HIV-positive
people, in which the comparator is the subset of the
general population that takes out life insurance rather than
the general population [7], can inform the promotion of
fair access to underwritten insurance for HIV-positive
individuals. By accounting for risk factors that have been
established as strongly prognostic for mortality [8], such
analyses can identify insurable subgroups and facilitate the
calculation of evidence-based ratings for longer term
insurance, based on extrapolation of current mortality
rates.We identify insurable subgroups of the HIV-positive
population in Europe, using data from European
cohorts participating in the ART Cohort Collaboration
(ART-CC).Methods
The ART-CC, described in detail elsewhere [9,10], is an
international collaboration of HIV cohort studies that
combines data on HIV-positive individuals who were
antiretroviral-naive when they started ART. Here,
eligible patients were participants in European cohorts,
aged at least 18 years, had presumed mode of transmission
that was not via IDU, and initiated ART between 1996
and 2008. All had CD4 cell count and HIV-1 RNA
measured in the 3 months before ART initiation, and
between 3 and 9 months after initiation. The included
cohorts, from six countries, were: the AIDS Therapy
Evaluation Project Netherlands (ATHENA); the Agencepincott Williams & Wilkins. UnauthoNationale de Recherches sur le SIDA et les he´patites
virales (ANRS) CO4 French Hospital Database on HIV
(FHDH) and ANRS CO3 Aquitaine Cohort, France;
Italian Cohort of Antiretroviral-Naive Patients
(ICONA); Royal Free Hospital Cohort, London United
Kingdom; Swiss HIV Cohort Study (SHCS); the
Cohorte de la Red de Investigacio´n en Sida (CoRIS),
the Proyecto para la Informatizacio´n del Seguimiento
Clı´nico-epidemiolo´gico de la Infeccio´n por HIV y SIDA
(PISCIS) Cohort, VACH, Spain; and the multicenter
study, EuroSIDA (restricted to patients from the selected
six countries). Data on follow-up for mortality were
available to 31 December 2009. Patients not known to
have died were considered lost to follow-up 3 months
after their last CD4 cell count measurement, except when
this was within 6 months of study end. Institutional
review boards from each cohort approved analysis of
routinely collected data.
Expected numbers of deaths according to age, sex and
country were calculated based on so-called ‘standard’
insured lives (those healthy lives accepted for life
insurance using standard premium rates without a health
loading). These were based on published insurance tables
where available (France, Netherlands, United Kingdom),
or on adjustments to population mortality tables (Italy,
Spain, Switzerland) commonly used in those markets by
pricing actuaries. The specific percentages used for each
market (country) were obtained from interviews with
Swiss Re (a reinsurance company with headquarters in
Zurich, Switzerland) regional pricing actuaries and were
based on their knowledge of pricing levels in those
markets. Such multiplicative adjustments reflected typical
industry pricing levels for individual life insurance in
2004, taking into account the risk assessment (under-
writing) practices in 2011 and accounts for insured lives
having lower mortality than general population lives.
Insurance mortality trends are a combination of the
underlying health and accident trends in the insured
population and the trends in (or changes in practice of)
how underwriters decide which lives belong to the pool
of insured persons with standard risk. For France we used
50% of mortality rates in actuarial tables TF00-02
(women) and 40% of TH00-02 (men), respectively
(www.institutdesactuaires.com/docs/2007017232113_
NOTICETHTF0002.pdf). For the Netherlands we used
55% of the respective GBM/V00-5 tables (www.ag-ai.nl/
download/10351-Prognosetafel+2005+-+2050.pdf p66).
For the UK we used 70% of TF00 and 60% of TM00,rized reproduction of this article is prohibited.
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ces/pages/00-series-mortality-tables-assured-lives-annuit
ants-and-pensioners). For Italy we used 55% of the
respective 2002 population mortality tables for each sex
published by the ItalianNational Institute of Statistics (table
SI 2002 www.istat.it). For Spain we used 45% of the 2006
population mortality and for Switzerland we used 80% of
the 2006 populationmortality (HumanMortalityDatabase
www.mortality.org).
The United Kingdom and Netherlands tables provided
rates by age and duration at policy inception: the effect of
duration generally decreases with increasing time since
the underwriting date and the rates after which there is no
substantial change with increasing duration are termed
‘ultimate’. The lives in the HIV study were not screened
through the normal insurance processes. It is, thus,
consistent to compare them with insurance rates where
the effects of such screening have worn off, which
correspond to the ‘ultimate rates’ in the comparator
insured population. Therefore, we used the ultimate rates,
which depend only on age, from these tables.
We graphed assumed mortality rates for insured lives
(using the above-mentioned tables) by age, sex and
country, and compared mortality rates for insured lives
and the general population by age and sex. The general
population reference was based on the human mortality
database (www.mortality.org) for 2004, and the rates for
each country weighted according to the person-years of
observation in the analysis dataset.
Data analyses used generalized linear models (GLM)
assuming a Poisson error distribution with log link
function [11] and with expected numbers of deaths based
on the insured population (person-years at risk multiplied
by the rate in the corresponding insured population)
according to age, sex and country specified as an offset
[12]. As we wished to model duration of ARTexplicitly,
we did not allow for it in the offset. The variables
considered for inclusion were country, sex, transmission
risk group (MSM, heterosexual contact, blood and
other), year of initiation of ART, age at start of ART,
AIDS diagnosis prior to ART and CD4 cell count and
HIV-1 RNA at start of ART and 6 months later (see
Table 1 for categorizations). The 6-month CD4 cell
count and HIV-1 RNA used in the analysis were those
measured closest to 6 months after start of ART and
within a window of 3–9 months. We additionally
considered for inclusion in the GLM three variables that
varied over time: calendar time (1996–2000, 2001–
2008), current age (20–29, 30–39, 40–49, 50–59,
60 years) and duration of ART since the 6-month
measurement (1–3, 4–6, 7–9, 10 years). Note that
duration of ART equal to 1–3 corresponds to the first
3 years after the 6-month measurement, and therefore
is follow-up time from 0.5 to 3.49 years after starting
ART.Copyright © Lippincott Williams & Wilkins. UnautStarting with a model including all variables, we removed
variables to find a model containing only variables with
clear associations (P< 0.05) with mortality and where the
residuals were not overly overdispersed or underdispersed.
The dispersion parameter measures both underdispersion
and overdispersion and should be close to one for a well
fitting Poisson model. We combined categories where
this improved model fit, and tested two-way, but not
higher-order, interactions. We chose the final model
based on dispersion parameter within 5% of 1, lower
Akaike Information Criterion (AIC) [13] and normality
of the distribution of Anscombe residuals [11]. In
sensitivity analyses we used P value less than 0.1 as the
threshold for variable selection and considered models
with a negative binomial distribution.
The final GLMwas used to estimate the relative mortality
of the group with reference values of all included
variables, compared with insured lives within the same
age and country group. The relative mortality of other
groups was derived by multiplying baseline relative
mortality bymortality rate ratios from the GLM. Potential
insurability is determined by the actual/expected claims
ratio (relative mortality multiplied by 100%). A claims
ratio of 100% represents no excess mortality, whereas
500%, or equivalently relative mortality 5, represents
400% excess mortality. Bounds for insurability are not
fixed, and therefore we illustrated the extent of excess
mortality by drawing plots of actual/expected claims
ratios with contours at 100, 250, 500, 750, 1000, 2000
and 3000% relative mortality, according to 6-month CD4
cell count, ART duration, age and calendar period of
ART initiation, among people with lower risk values of
other variables. StataTM version 12 and Microsoft Excel
2007 were used to perform analyses.Results
Among 34 680 patients followed for 174 906 person-years
there were 1236 deaths (overall mortality rate 0.71 [95%
confidence interval (CI) 0.67–0.75] per 100 person-
years). The majority of the data were from France and the
Netherlands (Table 1) and 70% of patients were men.
Crude mortality rates increased with age and were higher
for men and those with an AIDS diagnosis prior to
baseline. The association of lower CD4 cell count and
higher HIV-1 RNA with mortality was greater for 6-
month measurements than those at initiation of ART.
Crude mortality rates varied between countries and were
lower for the United Kingdom and Italian cohorts, which
may reflect true lower mortality or might be due to
sampling variability or incomplete death ascertainment.
Figure 1 (upper panel) shows mortality rates in the
insured population according to sex, age and country.
Differences in mortality rates between countries werehorized reproduction of this article is prohibited.
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Table 1. Characteristics of 34 680 HIV-positive patients included in the analyses.
Characteristic Category
Number of
patients (%)
No. of
deaths (%)
Crude mortality rate
per 100 person-years (95% CI)
Total 34 680 (100) 1236 (100) 0.71 (0.67–0.75)
Country France 19 503 (56) 684 (55) 0.71 (0.66–0.76)
Italy 1683 (5) 38 (3) 0.43 (0.29–0.58)
Netherlands 5718 (16) 250 (20) 0.78 (0.69–0.89)
Spain 3379 (10) 85 (7) 0.61 (0.48–0.75)
Switzerland 3209 (9) 147 (12) 0.82 (0.69–0.96)
UK 1188 (3) 32 (3) 0.53 (0.36–0.74)
Sex Female 10 504 (30) 216 (17) 0.44 (0.38–0.50)
Male 24 176 (70) 1020 (83) 0.81 (0.76–0.86)
Age at initiation of ART (years) 15–29 6891 (20) 118 (10) 0.34 (0.28–0.41)
30–49 22 437 (65) 685 (55) 0.59 (0.55–0.64)
50 5352 (15) 433 (35) 1.71 (1.54–1.87)
Year of ART initiation 1996–2000 13 005 (38) 765 (62) 0.76 (0.71–0.81)
2001–2004 12 807 (37) 375 (30) 0.64 (0.57–0.71)
2005–2008 8868 (26) 96 (8) 0.62 (0.50–0.75)
Transmission risk group MSM 13 845 (40) 497 (40) 0.66 (0.60–0.72)
Heterosexual 17 948 (52) 580 (47) 0.67 (0.62–0.73)
Blood 335 (1) 24 (2) 1.29 (0.83–1.93)
Other 2552 (7) 135 (11) 1.15 (0.96–1.35)
Baseline CD4 cell count (cells/ml) 350 8200 (24) 186 (15) 0.40 (0.34–0.46)
200 to 349 10 669 (31) 266 (22) 0.54 (0.47–0.60)
100 to 199 7020 (20) 263 (21) 0.79 (0.69–0.89)
50 to 99 3404 (10) 175 (14) 1.00 (0.85–1.16)
<50 5387 (16) 346 (28) 1.24 (1.11–1.38)
Six-month CD4 cell count (cells/ml) 350 17 001 (49) 349 (28) 0.40 (0.36–0.44)
200 to 349 9425 (27) 312 (25) 0.68 (0.61–0.76)
100 to 199 5689 (16) 275 (22) 0.95 (0.83–1.06)
50 to 99 1788 (5) 147 (12) 1.57 (1.32–1.84)
<50 777 (2) 153 (12) 4.61 (3.88–5.37)
Baseline HIV-1 RNA (copies/ml) <500 2683 (8) 63 (5) 0.57 (0.43–0.72)
500 to 1104 5053 (15) 148 (12) 0.58 (0.49–0.68)
1104 to 1105 12 265 (35) 376 (30) 0.59 (0.53–0.66)
1105 14 679 (42) 649 (53) 0.86 (0.80–0.93)
Six-month HIV-1 RNA (copies/ml) <500 24 725 (71) 685 (55) 0.60 (0.56–0.65)
500 to 1104 7298 (21) 313 (25) 0.65 (0.58–0.72)
1104 to 1105 1788 (5) 117 (9) 1.33 (1.09–1.58)
1105 869 (3) 121 (10) 3.01 (2.47–3.57)
Clinical CDC stage at baseline A/B 27 067 (78) 749 (61) 0.55 (0.51–0.59)
C 7613 (22) 487 (39) 1.25 (1.14–1.36)
ART, antiretroviral therapy; CDC, Centers for Disease Control.relatively small, UK men and women had the highest
mortality rates at most ages, whereas Spanish women had
the lowest mortality. Figure 1 (lower panel) shows the
lower mortality in the insured population compared with
the whole population, in both men and women.
The final model did not include sex: the model offset
effectively adjusted for sex as mortality rates were lower in
women in the insured population. CD4 cell count and
HIV-1 RNA at initiation of ART were not sufficiently
prognostic for inclusion in the final model, after
adjustment for 6-month values of those variables. Age
at initiation was not prognostic after adjustment for
current age. There was little difference between mortality
from 7–9 and at least 10 years duration of ART and so
these categories were combined. Similarly, categories for
starting ART in 2001–2004 and 2005–2008 were
combined, and HIV-1 RNA was dichotomized at
104 copies/ml. The dispersion parameter was lowest in
models that included all countries separately, andpyright © Lippincott Williams & Wilkins. Unauthotherefore groupings of countries were examined.
Comparing the two countries contributing most
person-years, Dutch lives experienced higher adjusted
relative mortality than French lives, partly because of the
lower standard mortality of the Dutch insured HIV-
negative population.We found little evidence that relative
mortality in the other included countries differed from
that of either France or the Netherlands, but that the best-
fitting model was obtained by grouping other countries
with France. After choosing prognostic variables and their
groupings and restricting to models with dispersion
parameter within 5% of 1, two models with similar AIC
and Anscombe residual distribution remained. We chose
the model that did not include transmission risk category,
as differential pricing of insurance based on slightly higher
mortality rates in individuals with transmission via blood
transfusion would be difficult to justify. The final model
did not include any interactions. Sensitivity analyses
indicated that variables selected for inclusion in the final
model were the same when the P value threshold wasrized reproduction of this article is prohibited.
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Fig. 1. Mortality rates according to age and country of insurance population (upper panels) and weighted European mortality
comparing insurance population and general population (lower panels).raised from 0.05 to 0.1 and that the selected Poisson
model fitted the data better than a negative binomial
model.
Mortality rate ratios for the variables included in the final
model are displayed in Table 2, which shows that CD4
cell count and viral load at 6 months were the most
strongly prognostic variables. Mortality rate ratios
decreased with age (P< 0.005) because increases in
mortality with age in HIV-positive people were less
marked than in comparator populations. Mortality rate
ratios decreased with ART duration and were higher for
those who initiated ART before 2001 (P< 0.005) or
who had an AIDS diagnosis prior to starting ART
(P< 0.005).Copyright © Lippincott Williams & Wilkins. UnautThe baseline group for comparison of mortality ratios was
patients aged 20–39 from France, Italy, United Kingdom,
Spain and Switzerland, who started ART after 2000, had
6-month CD4 cell count at least 350 cells/ml, 6-month
HIV-1 RNA< 104 copies/ml and no AIDS before ART
initiation, during the first 3 years of ART. The relative
mortality of this group compared with insured HIV-
negative lives in the same age group was 459% (95% CI
391–539). The relative mortality of other groups is
derived by multiplying by the corresponding mortality
rate ratios in Table 2. For example, patients aged
40–49 years with 6-month CD4 cell count 200–
349 cells/ml, who started ART before 2001 and otherwise
the same characteristics as the baseline group had relative
mortality 459% 0.53 1.44 1.33¼ 466% during thehorized reproduction of this article is prohibited.
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Table 2. Crude (univariable) and adjusted (multivariable) mortality rate ratios among 34 680 HIV-positive people included in analyses, based on
the final generalized linear model.
Characteristic Category
Mortality rate ratio (95% CI)
Crude (univariable) Adjusted (multivariable)
6 month CD4 cell count 0–49 10.75 (8.89–13.01) 6.84 (5.54–8.45)
(cells/ml) 50–99 3.17 (2.61–3.85) 2.71 (2.21–3.32)
100–199 1.87 (1.59–2.19) 1.76 (1.49–2.08)
200–349 1.44 (1.23–1.67) 1.44 (1.24–1.69)
350þ (M) 1.00 1.00
6 month HIV-1 RNA 0–1104 (M) 1.00 1.00
(copies/ml) 104 3.68 (3.19–4.24) 2.42 (2.08–2.82)
Region Countries excl. NL (M)(MM) 1.00 1.00
Netherlands 1.25 (1.09–1.44) 1.48 (1.28–1.70)
Current age 20–39 (M) 1.00 1.00
40–49 0.53 (0.46–0.61) 0.53 (0.46–0.62)
50–59 0.40 (0.34–0.47) 0.41 (0.35–0.48)
60þ 0.26 (0.22–0.30) 0.28 (0.24–0.34)
Duration of ART (years) 1–3 (M) 1.00 1.00
4–6 0.66 (0.58–0.75) 0.69 (0.61–0.79)
7þ 0.48 (0.41–0.56) 0.51 (0.43–0.61)
Clinical CDC stage at baseline Stage A/B (M) 1.00 1.00
Stage C 1.85 (1.65–2.08) 1.40 (1.23–1.58)
Year of ART initiation 1996–2000 1.06 (0.94–1.18) 1.33 (1.18–1.50)
2001–2008 (M) 1.00 1.00
ART, antiretroviral therapy; CDC, Centers for Disease Control. (M) The baseline, corresponding to the categories (M) above, is equal to an actual/
expected claims ratio of 459%. (MM) Countries excl. NL include France, Italy, Spain, Switzerland and the UK.
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Figure 2 shows contours of relative mortality according to
CD4 cell count and duration of treatment, separately
according to age group and calendar period of starting
ART, among patients with lower risk values of other
variables. Supplementary Table 1, http://links.lww.com/
QAD/A325 shows percentage relative mortality accord-
ing to risk factors for France, Italy, Spain, Switzerland,
and United Kingdom (illustrated in Fig. 2) and
supplementary Table 2, http://links.lww.com/QAD/
A325 shows relative mortality for the Netherlands. In
our study population (which excluded IDU or those who
were hepatitis C positive), the proportion of exposure
time with relative mortality below 300, 400, 500 and
600% was 28, 43, 61 and 64%, respectively.250
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Fig. 2. Percentage relative mortality compared with HIV-
negative insured lives (actual/expected claims ratio) of
HIV-positive people according to CD4 cell count 6 months
after start of ART, duration of ART, age group and calendar
period of initiation of ART, among individuals without an
AIDS diagnosis and with 6-month HIV-1 RNA less than
1000 copies/ml and in countries other than the Netherlands.
Typical bounds for insurability range between 400 and 500%.Discussion
We estimated the relative mortality of HIV-positive lives,
compared with insured HIV-negative lives in the same
population. Our results apply to HIV-positive individuals
who have survived at least 6 months after starting ART in
six European countries. Relative mortality was lower for
those who started ARTafter the year 2000 without a prior
AIDS diagnosis and who had 6-month CD4 cell count
greater than 350 cells/ml and 6-month HIV-1 RNA less
than 104 copies/ml. Relative mortality compared with
insured HIV-negative lives declined with increasing
duration of ART, and decreased with age despite
increases in mortality rates with age, a phenomenon that
has been observed in other studies of HIV populationspyright © Lippincott Williams & Wilkins. Unautho[14–16]. Because relative mortality varies with age and
with time on ART, no single result applies to any
particular insurance policy, our results must be used as arized reproduction of this article is prohibited.
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loadings so as to obtain a level of extra premium are
beyond the scope of this article. However, our results
imply that more than 50% of patients – those with lower
relative mortality – in an HIV-positive population with
similar risk profile to that analysed in this study could be
insurable, based on conventional limits to relative
mortality of 500%.
Our study was based on a large HIV-positive study
population, we analysed data from over 30 000 patients,
with long follow-up during whichmore than 1000 deaths
were recorded. We controlled for underwriting effects by
using ‘ultimate rates’, which factor out selection bias (see
above for further details). Data were only available to
estimate death rates up to 10 years after starting ART, and
therefore estimated excess mortality will have to be
extrapolated beyond the follow-up time that is currently
observable. However, most HIV-related mortality occurs
during the first few years of ART [17], and therefore
excess mortality rates beyond 7 years duration of ARTare
likely to be stable. Our estimates are likely to be
conservative for patients starting ART today on better
tolerated and more effective drug regimens than those for
patients included in analyses. A limitation of our study is
that there was only limited follow-up of older individuals:
6572 person-years (3.8% of the total follow-up time)
among persons aged more than 60 years. Therefore, death
rates above age 60 were imprecisely estimated. However,
demand for life insurance is mainly for lives under age 60
years. We excluded patients with presumed transmission
via IDU, as these are unlikely to be granted insurance
even if HIV negative. We did not have data on
socioeconomic status. However, bias should be small
because we used socioeconomic neutral mortality rates.
We did not have data on smoking, this could lead to a bias
if, for example, HIV-positive people were on average
more likely to smoke than other insured people. The
effect of this is likely to be relatively small, for example, a
doubling of the proportion of smokers would result in an
approximately 25% increase in mortality.
Our dataset included national databases on HIV-positive
people from France, the Netherlands and Switzerland;
these are likely to be representative of all patients in care in
these countries. Data from Spain were contributed by
many treatment centres from several regions, whereas
those from Italy and Germany were from a limited
number of clinics. All clinics provide comprehensive care
to HIV-positive people in their locality and are not
specialist referral centres. The majority of the data
analysed in this study were from France and the
Netherlands. We found relative mortality to be somewhat
higher in the Netherlands, partly because of relatively
lower mortality in Dutch insured HIV-negative lives. We
found little evidence that relative mortality in other
countries differed from that in France. We found little
evidence that effects of variables included in the finalCopyright © Lippincott Williams & Wilkins. Unautmodel differed between Dutch lives and those from other
countries. Our results may apply to other high-income
countrieswith good access to care but it would be desirable
to conduct further analyses of data from European
countries not represented here, as insurance policies vary
by country. In the USA, part of the HIV epidemic is in
sociallymarginalized populations [18,19], and access to free
healthcare is limited, for example, only thosewith anAIDS
diagnosis or with CD4 cell count less than 200 cells/ml are
eligible forMedicaid, although provisionwill be expanded
when the Affordable Care Act takes full effect in 2014 [20].
It is, therefore, unclear whether a similar proportion of
HIV-positive lives is potentially insurable, and a study based
on representative cohorts of HIV-positive people in the
USA is highly desirable. Similarly, there is an urgent need
for a study of insurability in South Africa, wherein the
prevalence ofHIV ismany times higher than in Europe and
there is also a high market penetration of life insurance.
Studies are also lacking in Japan, India, China and Brazil –
countrieswith potentially large insurancemarkets forHIV-
positive lives.
People newly diagnosed with HIV can be expected to
survive longer than those recruited to cohorts between
1996 and 2010, therefore, studies such as ours necessarily
provide trailing indicators of mortality rates. Attempts
have been made to allow for this problem in a computer
simulation model: estimated life expectancy of MSM
aged 30 years who became HIV positive in 2010 with no
hepatitis C infection and high CD4 cell count at start of
ART in the United Kingdom was 75 years (95% CI
68–77), a loss of only 7 years compared with the male UK
population [21], similar to the average loss of life because
of smoking.
Theoretically, insurability depends on the financial
resources of the person buying insurance as insurance
providers discriminate levels of risk, and price products
accordingly. However, to prevent fraud and antiselection,
insurers commonly apply their own insurability criteria
which include limits on insurance ratings. Practices vary
with a limit on the percentage extra mortality being the
commonest. We have assumed that ratings up to an excess
mortality of 400% (relative mortality 500%) are insurable.
Insurance ratings beyond these bounds have generally not
been accepted by the insurance buying public.
The Dutch Association of Insurers recommended in 2005
that short-term insurance should be made available to
successfully treated patients [22] and in 2009 that it should
be extended to patients who do not yet need ART [23].
Nevertheless, HIV-positive individuals have routinely
been turned down for life insurance, despite advances in
ARTand evidence its effectiveness [24]. Our study should
allow insurance providers to make a fair assessment of
risk in order to properly underwrite insurance for HIV-
positive people, for longer terms. Assuming that relative
mortality does not increase as time on ART increaseshorized reproduction of this article is prohibited.
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evidence that could allow life insurance up to 20 years term
to be offered to lower risk HIV-positive individuals, at
affordable premiums.Whole of life insurance at guaranteed
rates may become feasible when data on mortality with
longer duration of ART become available.
Remaining underwriting challenges include assessment
of likely future adherence to ART, the quality of medical
care, presence of comorbidities and drug interactions.
There are also pricing challenges due to extrapolation of
mortality rates beyond the 10 years’ follow-up analysed
here, and because HIV-positive individuals may apply for
insurance at any time prior to or during treatment, but
our estimates are based on CD4 cell count and HIV-1
RNA 6 months after ART initiation. Information on
CD4 trajectories and viral suppression can be used to map
from duration of ART to duration since taking out
insurance [25]. Most chronic diseases result in deterior-
ating health with time on medication, but HIV-positive
individuals on ART experience an increasing relative
benefit of treatment as their CD4 cell counts increase
towards normal levels, which may take more than 5 years
[14,26]. Therefore, the lives of people with HIV tend to
become more insurable with increasing duration of
successful ART. Insurance companies set bounds for
insurability for standard lives, including high age at
application (which vary considerably between insurers
and markets but could be as low as 60 years) as well as
restrictions based on prior or current recreational drug
use, which would also apply to HIV-positive lives. Our
model suggests poorer outcomes for those with AIDS
before start of ART. Insurers will have to interpret this
with caution as different AIDS-defining conditions have
substantially different implications for subsequent
mortality [27].
Many people living with HIV and starting ART with
currently recommended drugs and in accordance with
treatment guidelines will live a near-normal life span [21].
Lack of insurance products is no longer justified, as the
excess mortality of those with HIV is comparable to many
other groups with morbidities that are insured, such as
diabetics or cancer survivors. Our study provides data that
will allow the insurance market to open up to people
living with HIV. Life insurance could now be extended to
20 years, which would be particularly useful for mortgage
cover. We aim to communicate our results directly to
insurance providers in order that they can amend their
policies, with consequent improvements in the quality of
life for HIV-positive people.Acknowledgements
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